T2 Biosystems pulls in $40M in Series E funding round

03/29/2013 | American City Business Journals

A Series E funding round led by Goldman Sachs has brought in $40 million for T2 Biosystems. The Lexington, Mass.-based company will use the money to develop and commercialize its T2Candida test, which can detect Candida fungal infections known to cause sepsis from whole blood samples in under two hours.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC